Abstract: The present invention relates to compounds (e.g. ISVDs, polypeptides, polypeptide derivatives) capable of binding to Interleukin-6 (IL-6) and their use in the treatment of inflammatory diseases such as, e.g. cardiovascular disease (CVD).

Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.

Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.

Abstract: The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

Abstract: The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

Abstract: The invention relates to pharmaceutical compositions comprising a PCSK9 inhibitor, such as an EGF(A) peptide, and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

Abstract: The invention relates to pharmaceutical compositions comprising a GLP-1 agonist, an SLGT2 inhibitor, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and a hydrotrope. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

Abstract: The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

Abstract: A switch can be used in conjunction with a superconducting current path to provide a more reliable circuit and system. The switch can be connected in parallel with a portion of the superconducting current path. In one embodiment, the switch may be connected in parallel with an entire superconducting element, such as a persistent current switch, a superconducting coil, or the like, or may be connected in parallel across only a portion of a superconducting element. A method of using the system is also disclosed.

Abstract: A method can be used to perform an operation on a system that includes an assembly and a vessel that includes a wall and a thermal shield. The method can include breaking a thermal connection between the assembly and the thermal shield, separating the assembly and a surface within the vessel from each other, or any combination thereof. The method can also include changing a pressure with the vessel to be closer to atmospheric pressure, heating the assembly, or any combination thereof. In one embodiment, the method can be performed while keeping a cryogenic region substantially sealed, keeping a superconducting magnet energized, or a combination thereof. In a particular embodiment, the method can be used when servicing the assembly, such as a cryocooler.

Abstract: A superconducting magnetic element is provided wherein the terminals are bonded to the coil body and are independent of that coil body supporting structure. The technology employs a terminal structure with a supporting base member surrounding a conductor terminal end portion positioned on a surface of an impregnated coil body and integrally bonded thereto. The terminal structure in turn permits freedom in manufacturing to employ all useful strategies in accommodating physical properties of different materials.